Follow
Marek Pruszynski
Marek Pruszynski
National Centre for Nuclear Research
Verified email at ncbj.gov.pl
Title
Cited by
Cited by
Year
Astatine-211: production and availability
M R Zalutsky, M Pruszynski
Current radiopharmaceuticals 4 (3), 177-185, 2011
1432011
131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer TreatmentTheranostic 131I-labeled Anti-HER2 sdAb for Cancer Treatment
M D'Huyvetter, J De Vos, C Xavier, M Pruszynski, YGJ Sterckx, S Massa, ...
Clinical Cancer Research 23 (21), 6616-6628, 2017
1042017
Post-elution processing of 44Ti/44Sc generator-derived 44Sc for clinical application
M Pruszyński, NS Loktionova, DV Filosofov, F Rösch
Applied Radiation and Isotopes 68 (9), 1636-1641, 2010
1032010
Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody
M Pruszynski, E Koumarianou, G Vaidyanathan, H Revets, N Devoogdt, ...
Nuclear medicine and biology 40 (1), 52-59, 2013
952013
Radiolabeling of DOTATOC with the long-lived positron emitter 44Sc
M Pruszyński, A Majkowska-Pilip, NS Loktionova, E Eppard, F Roesch
Applied Radiation and Isotopes 70 (6), 974-979, 2012
802012
Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling
M Pruszynski, E Koumarianou, G Vaidyanathan, H Revets, N Devoogdt, ...
Journal of nuclear medicine 55 (4), 650-656, 2014
772014
New measurement of excitation functions for (p, x) reactions on natMo with special regard to the formation of 95mTc, 96m+ gTc, 99mTc and 99Mo
O Lebeda, M Pruszyński
Applied Radiation and Isotopes 68 (12), 2355-2365, 2010
772010
Evaluation of an Anti-HER2 Nanobody Labeled with 225Ac for Targeted α-Particle Therapy of Cancer
M Pruszynski, M D’Huyvetter, F Bruchertseifer, A Morgenstern, T Lahoutte
Molecular Pharmaceutics 15 (4), 1457-1466, 2018
702018
Trastuzumab-Modified Gold Nanoparticles Labeled with 211At as a Prospective Tool for Local Treatment of HER2-Positive Breast Cancer
Ł Dziawer, A Majkowska-Pilip, D Gaweł, M Godlewska, M Pruszyński, ...
Nanomaterials 9 (4), 632, 2019
582019
Radiolabeling and in vitro evaluation of 67Ga-NOTA-modular nanotransporter–A potential Auger electron emitting EGFR-targeted radiotherapeutic
E Koumarianou, TA Slastnikova, M Pruszynski, AA Rosenkranz, ...
Nuclear medicine and biology 41 (6), 441-449, 2014
542014
Gold nanoparticle bioconjugates labelled with 211 At for targeted alpha therapy
L Dziawer, P Koźmiński, S Męczyńska-Wielgosz, M Pruszyński, M Łyczko, ...
RSC advances 7 (65), 41024-41032, 2017
422017
Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with 225Ac as a Perspective Tool for Combined α-Radioimmunotherapy and …
E Cędrowska, M Pruszyński, W Gawęda, M Żuk, P Krysiński, ...
Molecules 25 (5), 1025, 2020
402020
Preparation of Rh[16aneS4-diol]211At and Ir[16aneS4-diol]211At Complexes as Potential Precursors for Astatine Radiopharmaceuticals. Part I: Synthesis
M Pruszynski, A Bilewicz, MR Zalutsky
Bioconjugate chemistry 19 (4), 958-965, 2008
402008
Functionalized TiO2 nanoparticles labelled with 225Ac for targeted alpha radionuclide therapy
E Cędrowska, M Pruszynski, A Majkowska-Pilip, S Męczyńska-Wielgosz, ...
Journal of Nanoparticle Research 20 (3), 1-10, 2018
392018
Adsorption of 137Cs on titanate nanostructures
B Filipowicz, M Pruszyński, S Krajewski, A Bilewicz
Journal of Radioanalytical and Nuclear Chemistry 301 (3), 889-895, 2014
282014
Production and supply of α-particle–emitting radionuclides for targeted α-therapy
V Radchenko, A Morgenstern, AR Jalilian, CF Ramogida, C Cutler, ...
Journal of Nuclear Medicine 62 (11), 1495-1503, 2021
242021
Trastuzumab-Modified Gold Nanoparticles Labeled with 211 At as a Prospective Tool for Local Treatment of HER2-Positive Breast Cancer.
A Majkowska-Pilip, D Gaweł, M Godlewska, M Pruszyński, J Jastrzębski, ...
Nanomaterials 9, 632, 2019
222019
211At labeled substance P (5–11) as potential radiopharmaceutical for glioma treatment
M Lyczko, M Pruszynski, A Majkowska-Pilip, K Lyczko, B Was, ...
Nuclear Medicine and Biology 53, 1-8, 2017
222017
N-Succinimidyl 3-((4-(4-[18 F] fluorobutyl)-1 H-1, 2, 3-triazol-1-yl) methyl)-5-(guanidinomethyl) benzoate ([18 F] SFBTMGMB): a residualizing label for 18 F-labeling of …
G Vaidyanathan, D McDougald, J Choi, M Pruszynski, E Koumarianou, ...
Organic & biomolecular chemistry 14 (4), 1261-1271, 2016
222016
N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: Influence of isomeric substitution on radiolabeling and target cell residualization
J Choi, G Vaidyanathan, E Koumarianou, D McDougald, M Pruszynski, ...
Nuclear medicine and biology 41 (10), 802-812, 2014
172014
The system can't perform the operation now. Try again later.
Articles 1–20